Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent ...

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

Scientists have discovered that a specific type of bacteria found in the gut may play a key role in triggering rheumatoid ...

The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

Researchers say study provides sufficient rationale to further explore the therapeutic uses of SSRIs during infection.

CSL has received approval from the EC for Andembry (garadacimab) to prevent recurrent attacks of HAE in patients aged 12 ...

The CDC estimates that the 2024-2025 flu season has already resulted in at least 24 million illnesses, 310,000 ...

If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...